Finance

Lists
Why is MYGN down २.५५%?
Dive Deeper
MYGN:NASDAQ
Myriad Genetics Inc
US$ ४.२०
-२.५५%
(-०.११) 1D
US$ ४.१२
-१.९०% (-०.०८०)
After hours
Closed: अक्टोबर १२, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MYGN...
Open
US$ ४.३०
High
US$ ४.३२
Low
US$ ४.१९
Avg. vol.
२०.३७ लाख
Volume
१३.८१ लाख
52-wk high
US$ ८.५९
52-wk low
US$ २.७४
EPS
-US$ १.२०
Beta
१.६४
Shares outstanding
९.५६ करोड
Open
US$ ४.३०
High
US$ ४.३२
Low
US$ ४.१९
Avg. vol.
२०.३७ लाख
Volume
१३.८१ लाख
52-wk high
US$ ८.५९
52-wk low
US$ २.७४
EPS
-US$ १.२०
Beta
१.६४
Shares outstanding
९.५६ करोड
News stories
From web sources and news partners
BioSpace
BioSpace
·
२९ मिनेट पहिले
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 12, 2026
The Chronicle-Journal
The Chronicle-Journal
·
९ मिनेट पहिले
What To Expect From Progressive’s (PGR) Q3 Earnings
Simply Wall Street
Simply Wall Street
·
४८ मिनेट पहिले
Sat Out Gilead Sciences' Rally? Here Is What Holders Saw
Stocktwits
Stocktwits
·
१ घण्टा पहिले
Big Banks Kick Off Q3 Earnings With S&P 500 Near Records — Strategists Flag What Could Move Markets
About Myriad Genetics Inc
CEOPaul J. Diaz
Employees-
Founded१९९२
Headquarters-
Sector-
Websitemyriad.com
Analyst ratings
Based on 8 analysts giving stock ratings to MYGN in the past 3 months
Hold
Buy
1
Hold
4
Sell
3
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for MYGN in the last 3 months.
Highest
Current US$ ४.२०
US$ ८.०० (+९०.४८%)
Average
US$ ३.७६ (-१०.४८%)
Lowest
US$ २.०० (-५२.३८%)
Analyst
Recommendation
Action
Price target
Projected
Date
William Bonello
Craig-Hallum
Buy
Maintained
US$ ८.००
+९०.५%
10/02/2026
Unknown Analyst
UBS
Hold
Initiated
US$ ३.६०
-१४.३%
09/08/2026
Doug Schenkel
UBS
Hold
Maintained
US$ ३.६०
-१४.३%
09/09/2026
David Westenberg
Piper Sandler
Sell
Downgraded
US$ २.००
-५२.४%
09/01/2026
Unknown Analyst
Jefferies
Sell
Maintained
US$ २.५०
-४०.५%
08/21/2026
Mason Carrico
Stephens
Hold
Reiterated
US$ ३.००
-२८.६%
08/18/2026
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
08/03/2026
Michael Ryskin
Bank of America Securities
Sell
Reiterated
US$ ३.२०
-२३.८%
08/03/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
US$ ३.००
-२८.६%
08/02/2026
Kyle Boucher
TD Cowen
Hold
Reiterated
US$ ४.००
-४.८%
07/31/2026
Daniel Brennan
TD Cowen
Hold
Reiterated
US$ ४.००
-४.८%
07/31/2026
Lu Li
UBS
Hold
Maintained
US$ ६.००
+४२.९%
02/25/2026
Previous reports
Loading Previous Earnings...
Revenue
Net income
Revenue
Cost of goods sold
Cost of revenue
Research and development expenses
Total research and development expenses
Selling, general, and admin expenses
Operating expense
Total operating expenses
Operating income
Other non operating income
EBT including unusual items
EBT excluding unusual items
Income tax expense
Effective tax rate
Other operating expenses
Net income
Net profit margin
Earnings per share
Interest and investment income
Interest expense
Net interest expenses
Depreciation and amortization charges
EBITDA
Gain or loss from assets sale
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू